PBYI Quote, Financials, Valuation and Earnings

Rocket Pharmaceuticals has a net margin of 6.46% compared to Puma Biotechnology's net margin of --. Puma Biotechnology's return on equity of 52.9% beat Rocket Pharmaceuticals's return on equity of --.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -12.79%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $9.03 which suggests that it could grow by 276.46%. Given that Rocket Pharmaceuticals has higher upside potential than Puma Biotechnology, analysts believe Rocket Pharmaceuticals is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.287, which suggesting that the stock is 28.736% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.232%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Puma Biotechnology's net income of $3M is higher than Rocket Pharmaceuticals's net income of -$61.3M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.47x while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of 6.46% compared to Puma Biotechnology's net margin of -271.3%. Puma Biotechnology's return on equity of 52.9% beat Spero Therapeutics's return on equity of -108.26%.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -12.79%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 102.43%. Given that Spero Therapeutics has higher upside potential than Puma Biotechnology, analysts believe Spero Therapeutics is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.287, which suggesting that the stock is 28.736% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Puma Biotechnology's net income of $3M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.47x while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus 4.76x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vor Biopharma has a net margin of 6.46% compared to Puma Biotechnology's net margin of --. Puma Biotechnology's return on equity of 52.9% beat Vor Biopharma's return on equity of --.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -12.79%. On the other hand Vor Biopharma has an analysts' consensus of $1.18 which suggests that it could fall by -44.58%. Given that Vor Biopharma has more downside risk than Puma Biotechnology, analysts believe Puma Biotechnology is more attractive than Vor Biopharma.

Puma Biotechnology has a beta of 1.287, which suggesting that the stock is 28.736% more volatile than S&P 500. In comparison Vor Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Vor Biopharma pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Vor Biopharma quarterly revenues of --. Puma Biotechnology's net income of $3M is higher than Vor Biopharma's net income of -$32.5M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.47x while Vor Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus -- for Vor Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.46% compared to Puma Biotechnology's net margin of 23.33%. Puma Biotechnology's return on equity of 52.9% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -12.79%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Vertex Pharmaceuticals has higher upside potential than Puma Biotechnology, analysts believe Vertex Pharmaceuticals is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.287, which suggesting that the stock is 28.736% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Puma Biotechnology's net income of $3M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.47x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.